Metrics as of 10/17/2026, 04:09 AM (Berlin time), refresh in progress.
HLS Therapeutics Stock
HLS Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- CEO
- Craig Stuart Millian
- Employees
- 85
- Market cap
- $127 M
- IPO
- 14/03/2018
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The…
HLS Therapeutics stock: price history
1D
-1.0%
1W
+0.2%
1M
+1.7%
6M
-11.8%
YTD
-14.9%
1Y
-27.3%
2Y
+4.9%
5Y
-78.6%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~21% stronger price swings than usual
Ask the agents about HLS Therapeutics
Analyst assessment of HLS Therapeutics
0
STRONG BUY
0
BUY
1
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Hold
As of: 18/03/2024
HLS Therapeutics stock metrics
P/E
-10.35
P/B
1.69
EV/EBITDA
6.17
RETURN ON EQUITY
-1.8%
NET MARGIN
-7.0%
DEBT/EQUITY
0.76
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.3%
FLOAT SHARES
30,706,459
AVG. DAILY VOLUME (30D)
82,701
Dividends
Comparable stocks
Frequently asked questions about HLS Therapeutics stock
What does HLS Therapeutics do?
HLS Therapeutics Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in Canada.
The CEO is Craig Stuart Millian, the company employs around 85 people.
The IPO was on 14/03/2018; the stock trades on TSX under the ticker HLS.TO.
What do analysts say about HLS Therapeutics stock?
1 analysts rate the stock, the consensus is Hold (as of 18/03/2024).
This is an external assessment, not a statement by Market Jury.
When does HLS Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 21% stronger than usual.
Does HLS Therapeutics pay a dividend?
Yes. The last dividend was CA$0.05 per share, ex-date 27/04/2023, paid on 15/06/2023.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to HLS Therapeutics?
Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
How can I get HLS Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess HLS Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.